Anca Chelariu-Raiciu, F. Trillsch, P. Harter, Ralf Strobl, J. Sehouli, P. Wimberger, Holger Bronger, Catherine Shannon, C. Lefeuvre, Joern Rau, L. Hanker, Stephan Polterauer, Frederik Marmé, A. El-Balat, Martin R. Stockler, N. Gregorio, Ros Glasspool, Sven Mahner, Alain Lortholary, Jacobus Pfisterer
{"title":"803 复发性卵巢癌二线铂类化疗患者在接受抗血管生成治疗后使用贝伐单抗的疗效和安全性--AGO-OVAR 2.21 III 期试验的亚组分析","authors":"Anca Chelariu-Raiciu, F. Trillsch, P. Harter, Ralf Strobl, J. Sehouli, P. Wimberger, Holger Bronger, Catherine Shannon, C. Lefeuvre, Joern Rau, L. Hanker, Stephan Polterauer, Frederik Marmé, A. El-Balat, Martin R. Stockler, N. Gregorio, Ros Glasspool, Sven Mahner, Alain Lortholary, Jacobus Pfisterer","doi":"10.1136/ijgc-2024-esgo.48","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":517822,"journal":{"name":"Oral Sessions","volume":"34 2","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"803 Efficacy and safety of bevacizumab following prior anti-angiogenic treatment in patients with second-line platinum- based chemotherapy in recurrent ovarian cancer – a subgroup analysis of the AGO-OVAR 2.21 phase III trial\",\"authors\":\"Anca Chelariu-Raiciu, F. Trillsch, P. Harter, Ralf Strobl, J. Sehouli, P. Wimberger, Holger Bronger, Catherine Shannon, C. Lefeuvre, Joern Rau, L. Hanker, Stephan Polterauer, Frederik Marmé, A. El-Balat, Martin R. Stockler, N. Gregorio, Ros Glasspool, Sven Mahner, Alain Lortholary, Jacobus Pfisterer\",\"doi\":\"10.1136/ijgc-2024-esgo.48\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":517822,\"journal\":{\"name\":\"Oral Sessions\",\"volume\":\"34 2\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Oral Sessions\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1136/ijgc-2024-esgo.48\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oral Sessions","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/ijgc-2024-esgo.48","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
803 Efficacy and safety of bevacizumab following prior anti-angiogenic treatment in patients with second-line platinum- based chemotherapy in recurrent ovarian cancer – a subgroup analysis of the AGO-OVAR 2.21 phase III trial